Short answer: Yes. Tirzepatide is covered by multiple Eli Lilly patent families around the molecule itself (composition-of-matter), its lipidation/modified forms, formulations, and its use in treating conditions like type 2 diabetes and obesity. These families include US, European (EP), and international (WO/PCT) filings, with earliest priority in the 2010s. Patent terms plus any extensions typically push potential expiry into the 2030s, but the exact dates depend on the specific family and any term adjustments or data exclusivities.
What you might be looking for
- Molecule/composition patents: cover tirzepatide itself (the specific peptide sequence and related salts/variants).
- Formulation and salt patents: cover dosage forms, carriers, and long-acting versions (e.g., fatty acid chain for half-life extension).
- Method-of-use patents: cover treating type 2 diabetes, obesity, and related metabolic diseases with tirzepatide.
- Manufacturing/process patents: cover synthesis and purification processes.
- Combination and delivery patents: cover co-therapy with other drugs or specific regimens.
If you want concrete details
- I can pull the current patent landscape and list key families with patent numbers, jurisdictions, status (granted/pending/expired), and expiration estimates.
- I can also provide tips on how to search yourself (USPTO, Google Patents, Espacenet, WIPO PATENTSCOPE) using terms like “tirzepatide,” “GIP GLP-1 dual agonist,” “Mounjaro,” and Lilly-related internal codes.
Would you like me to perform a targeted patent search and summarize the main families with numbers and expiry estimates for a specific jurisdiction (e.g., US, EU, or worldwide)?